Skip to content
DataLookout
Menu

NCT07887750

REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Occurrence of Dose-Limiting Toxicities (DLTs) during the DLT observation period
Timeframe: Up to 28 days
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 2 years
Severity of TEAEs
Timeframe: Up to approximately 2 years

Secondary (10)

Concentration of REGN9220 in serum when given in combination with odronextamab
Concentration of odronextamab in serum when given in combination with REGN9220
Occurrence of Anti-Drug Antibodies (ADA) to REGN9220
Magnitude of ADA to REGN9220
Occurrence of ADA to odronextamab
Show 5 moreShow less
Magnitude of ADA to odronextamab
Best Overall Response (BOR)
Complete Response (CR)
Progression-Free Survival (PFS)
Duration Of Response (DOR)

Arms and interventions

REGN9220 + OdronextamabExperimental

Drugs: REGN9220, Odronextamab